Jeremie Calais, MD

Key opinion leaders offer insights on closing knowledge gaps and highlight crucial factors for physicians to consider when interpreting gallium-based PET imaging results in clinical practice.

Medical experts address challenges and propose solutions for inter-readability concerns in nuclear medicine, particularly focusing on strategies to overcome the scarcity of specialized readers.

Key opinion leaders explore the significance of interdisciplinary collaboration in prostate cancer management, with a focus on how PSMA PET imaging enhances decision-making processes within multidisciplinary care teams.

Jaideep Sohi, MD, and Jeremie Calais, MD, conduct a comparative assessment of gallium-based and non-gallium-based imaging agents for their efficacy in detecting and characterizing oligometastatic prostate cancer.

Medical experts conduct a comparative assessment of gallium-based and non-gallium-based imaging agents to determine their efficacy in detecting and characterizing oligometastatic prostate cancer.

Jaideep Sohi, MD, and Jeremie Calais, MD, explore the complexities of managing oligometastatic disease, emphasizing the critical role of accurately assessing lesion counts, metastatic spread, and disease thresholds in optimizing clinical outcomes.

Key opinion leaders examine the role of advanced imaging agents, particularly PSMA PET and other radiotracers, in identifying and defining oligometastatic disease in patients with prostate cancer.

Experts in radiology imaging evaluate the impact and efficacy of PSMA PET in improving early detection methods and refining prostate cancer staging processes.

Key opinion leaders analyze the advantages of integrating PSMA PET imaging with traditional imaging techniques to enhance prostate cancer management and treatment strategies.

Jaideep Sohi, MD, and Jeremie Calais, MD, examine the comparative merits of PSMA PET and Gallium-Based PET while exploring the application of NCCN Guidelines in prostate cancer imaging protocols.